Biotech News
Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea (uGC)
Blujepa is the first in a new antibiotic class for the treatment of gonorrhoea approved in over three decades.
Related news
REGNRegeneron Pharmaceuticals2026-06-22 11:00 EST
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
INBXInhibrx2026-06-15 13:15 EST
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
RVMDRevolution Medicines2026-07-22 20:05 EST
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
REPLReplimune Group2026-08-06 20:00 EST
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
REPLReplimune Group2026-07-30 22:15 EST
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
GSKGSK plc2026-07-22 11:21 EST
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
SRPTSarepta Therapeutics2026-06-30 12:30 EST
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Stock data
- Close
- 52.17 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States